Preliminary study on identification of estrogen receptor-positive breast cancer subtypes based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) texture analysis

Hui Wang¹, Yunting Hu¹, Hui Li¹, Yuanliang Xie¹, Xiang Wang¹, Weijia Wan²

¹Department of Radiology, The Central Hospital of Wuhan, ²Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wahan 430030, China

Contributions: (I) Conception and design: W Wan; (II) Administrative support: H Wang; (III) Provision of study materials or patients: Y Hu; (IV) Collection and assembly of data: Y Xie; (V) Data analysis and interpretation: X Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Weijia Wan. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China. Email: wanweijia2019@163.com.

Background: Currently, breast cancer is divided into Luminal A, Luminal B, HER-2 overexpression (HER-2) and basal cell at genetic level. However, the differential diagnosis of estrogen receptor (ER)-positive breast cancer subtypes is rare. Therefore, we aimed to investigate the feasibility of identifying the ER-positive breast cancer subtypes based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) texture analysis.

Methods: A retrospective analysis was performed for clinical data of 51 patients with ER-positive breast invasive ductal carcinoma confirmed by surgery and pathology from January 20 to October 2018. FireVoxel texture analysis software was used to delineate the tumor boundary layer by layer. The differences in the above characteristics between Luminal A and Luminal B breast cancer were compared, and the diagnostic efficacy of statistically significant texture parameters for ER-positive breast cancer subtypes was analyzed.

Results: There were no significant differences in mean, standard deviation (SD), skewness and tumor size between Luminal A and Luminal B groups (P>0.05). The kurtosis, inhomogeneity and entropy could effectively distinguish between the two groups with statistically significant difference (P=0.001, P=0.000, and P=0.000). The area under the receiver operating characteristic (ROC) curve (AUC) of kurtosis, inhomogeneity and entropy diagnosed with malignant mass were 0.832, 0.859 and 0.891, respectively (P<0.01). In addition, the entropy was the best among the three indicators. When the entropy was ≤4.22, the sensitivity of the diagnosis Luminal B was 90.62% and the specificity was 78.95%.

Conclusions: The texture analysis features based on DCE-MRI can help to identify ER-positive breast cancer subtypes. Entropy can be the best single texture indicator.

Keywords: Breast cancer; estrogen receptor (ER); dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI); texture analysis

doi: 10.21037/gs.2020.04.01
View this article at: http://dx.doi.org/10.21037/gs.2020.04.01

Introduction

Worldwide, breast cancer has developed into the leading cause of cancer death in women (1). Currently, breast cancer is divided into four molecular types at the genetic level in medicine, including Luminal A, Luminal B, HER-2 overexpression (HER-2) and basal cell (basal like) (2). Among them, Luminal A and Luminal B breast cancer histopathology are expressed as positive estrogen receptor...
(ER), and/or positive progesterone receptor (PR), so they collectively referred to as ER positive breast cancer. ER-positive breast cancer is the most common types, accounting for 60% to 80% of all breast cancers (3). Molecular typing of ER-positive breast cancer has significant implications for the choice of treatment regimen and patient prognosis. The prognosis of patients with ER-positive early breast cancer in the first 5 years after surgery is better than that in patients with negative hormone receptors, and the prognosis is relatively poor, with 5–15 years after diagnosis (4).

Immunohistochemistry is commonly used in clinical work to determine molecular typing, which is not only invasive but also time consuming. In many areas of oncology, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has proven to be a clinically useful, non-invasive functional imaging technique to quantify tumor vasculature and tumor perfusion characteristics (5).

Texture analysis is an emerging computer-aided diagnosis technology that can quantitatively display subtle changes in image pixels and arrangement, independence of image grayscale and subjective factors of the diagnostics, and its evaluation value for various tumor heterogeneities is obtained. It has generally been confirmed that it has gradually become a research hotspot in recent years (6-9).

However, the differential diagnosis of ER-positive breast cancer subtypes is rare. Therefore, the purpose of this study was to explore the feasibility of using DCE-MRI texture analysis to distinguish Luminal A breast cancer and Luminal B breast cancer.

**Methods**

**Subjects**

This study was a retrospective analysis. Patients with ER-positive breast invasive ductal carcinoma confirmed by surgery and pathology from January 20 to October 2018 were included in this study. Inclusion criteria: (I) patients who were confirmed by pathology as ER-positive breast invasive ductal carcinoma; (II) patients with intact mammary gland DCE-MRI data; (III) patients whose image quality and shooting conditions met diagnostic criteria. Exclusion criteria: patients undergoing puncture or neoadjuvant chemotherapy before imaging examination. Finally, 51 patients were enrolled, including 19 patients with Luminal A, with an average age of (50.59±7.73) years, and 32 patients with Luminal B, with an average age of (54.34±12.73) years. All patients with breast cancer underwent tumor resection within 1 week after magnetic resonance (MR) examination and were confirmed by pathological examination. Before performing this study, all patients signed informed consent form, and this study was approved by the Ethics Committee of The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology.

**Breast DCE-MRI image acquisition**

The PHILIPS Achieva 3.0T TX superconducting MR scanner with an 8-channel double-cavity breast phased array coil was used. Dynamic enhanced scanning was performed by dyn-eTHRIVE sequence volume imaging, with TR/TE of 4.7 ms/2.3 ms and volume of 1 mm in all positions. The mask was scanned before dynamic enhancement, then the high-pressure syringe was used to inject the Magnevist 0.2 mmol/kg through the elbow vein, then bolus injection of 30 mL normal saline in 2 mL/s. Dynamic enhanced scan was immediately performed after the end of the injection. One phase per minute was acquired, and the entire scan sequence collected a total of 8 phases. The MR imaging findings of all patients were independently performed by two senior imaging diagnosticians. Dynamically enhanced scanning of the third phase image were selected (10,11).

**Texture analysis**

The selected images were imported into the computer aided diagnostic platform Firevoxel (Firevoxel; Center for Advanced Imaging Innovation and Research (CAI2R), New York University School of Medicine, New York, NY, USA) in DICOM format for analysis. Follow the blind law principle, two mammography MR diagnosticians (working years were 12 and 6 years respectively) manually sketched and filled the area of interest (ROI). Tumor ROI was manually defined on the selected images. The PHILIPS Achieva 3.0T TX superconducting MR scanner with an 8-channel double-cavity breast phased array coil was used. Dynamic enhanced scanning was performed by dyn-eTHRIVE sequence volume imaging, with TR/TE of 4.7 ms/2.3 ms and volume of 1 mm in all positions. The mask was scanned before dynamic enhancement, then the high-pressure syringe was used to inject the Magnevist 0.2 mmol/kg through the elbow vein, then bolus injection of 30 mL normal saline in 2 mL/s. Dynamic enhanced scan was immediately performed after the end of the injection. One phase per minute was acquired, and the entire scan sequence collected a total of 8 phases. The MR imaging findings of all patients were independently performed by two senior imaging diagnosticians. Dynamically enhanced scanning of the third phase image were selected (10,11).

The selected images were imported into the computer aided diagnostic platform Firevoxel (Firevoxel; Center for Advanced Imaging Innovation and Research (CAI2R), New York University School of Medicine, New York, NY, USA) in DICOM format for analysis. Follow the blind law principle, two mammography MR diagnosticians (working years were 12 and 6 years respectively) manually sketched and filled the area of interest (ROI). Tumor ROI was manually defined on the selected images. The PHILIPS Achieva 3.0T TX superconducting MR scanner with an 8-channel double-cavity breast phased array coil was used. Dynamic enhanced scanning was performed by dyn-eTHRIVE sequence volume imaging, with TR/TE of 4.7 ms/2.3 ms and volume of 1 mm in all positions. The mask was scanned before dynamic enhancement, then the high-pressure syringe was used to inject the Magnevist 0.2 mmol/kg through the elbow vein, then bolus injection of 30 mL normal saline in 2 mL/s. Dynamic enhanced scan was immediately performed after the end of the injection. One phase per minute was acquired, and the entire scan sequence collected a total of 8 phases. The MR imaging findings of all patients were independently performed by two senior imaging diagnosticians. Dynamically enhanced scanning of the third phase image were selected (10,11).
**Molecular typing standard**

The molecular subtypes of ER-positive breast cancer were defined as follows according to the 2017 edition of the Guidelines and Specifications for Breast Cancer Diagnosis and Treatment in China (12) (Table 1).

**Statistical analysis**

Statistical analysis was performed using SPSS 19.0 software. Measurement data were expressed as means ± standard deviation (x ± s). Independent sample t-test was used for comparison between groups; receiver operating characteristic (ROC) curve was established by Medcalc software for statistically different parameters between the two groups, the area under the curve (AUC) was calculated, the critical value was determined, and its differential diagnosis efficiency between the two subtypes was evaluated. P<0.05 was considered statistically significant.

**Results**

**Schematic diagram of single layer target area of Luminal A and Luminal B types**

DCE-MRI was performed for 51 patients, the representative diagram of single layer target area for patient with Luminal A and Luminal B types were shown in Figure 1A,B.

---

**Figure 1** The schematic diagram and the texture analysis results histogram and output value of the DCE-MRI axial monolayer target area of breast tumor. (A) Schematic diagram of the delineation of the DCE-MRI axial monolayer target in a 38-year-old female Luminal A breast cancer patient; (B) preoperative DCE-MRI dynamic T1WI pressure-reducing axial monolayer target area sketching for the 47-year-old female Luminal B breast cancer patients; (C,D) the entire tumor target area after the completion of the texture analysis results histogram and output value interface for corresponding patients. DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; T1WI, T1 weighted image.
Histogram and output value interface for texture analysis results after the completion of the entire tumor target area of Luminal A and Luminal B types could be found in Figure 1C, D.

**Results of texture analysis**

As shown in Table 2, there were no significant differences in mean, standard deviation, skewness, and volume between Luminal A and Luminal B. However, the other three characteristics (peak, inhomogeneity, and entropy) were statistically significant (P<0.01). Among them, the kurtosis in Luminal A type was significantly smaller than that in Luminal B type (P<0.01); while heterogeneity and entropy in Luminal A type were markedly larger than those in Luminal B type (P<0.01, respectively) (Figure 2).

Table 1: Detection and determination of markers for molecular typing of ER-positive breast cancer

<table>
<thead>
<tr>
<th>Molecular types</th>
<th>Markers</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luminal A</td>
<td>Luminal A-like: ER/PR positive and high PR expression, HER-2 negative, Ki-67 low expression</td>
<td>The determination of the expression of ER, PR, and Ki-67 suggests the percentage of cells that report positive cells. The judgment value of Ki-67 high and low expression may be different in different pathological experiment centers, and 14% can be used as a judgment to further distinguish Luminal A-like and Luminal B-like (HER-2 negative)</td>
</tr>
<tr>
<td>Luminal B</td>
<td>Luminal B-like (HER-2 negative): ER/PR positive HER-2 negative and high expression of Ki-67 or low expression of PR Luminal B-like (HER-2 positive): ER/PR positive, HER-2 positive (protein overexpression or gene amplification), Ki-67 in any state</td>
<td>The aforementioned Luminal-like tumors that do not meet the “Luminal A-like” condition can be used as “Luminal B-like” subtypes</td>
</tr>
</tbody>
</table>

ER, estrogen receptor; PR, progesterone receptor.

Table 2: Comparison of texture analysis results between Luminal A and Luminal B breast cancer patients

<table>
<thead>
<tr>
<th>Type</th>
<th>Cases</th>
<th>Texture analysis results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Signal mean</td>
</tr>
<tr>
<td>Luminal A</td>
<td>19</td>
<td>147.00±63.04</td>
</tr>
<tr>
<td>Luminal B</td>
<td>32</td>
<td>214.22±151.46</td>
</tr>
<tr>
<td>t value</td>
<td></td>
<td>−1.836</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>0.072</td>
</tr>
</tbody>
</table>

Note: The data in the table is represented by x ± s (normal distribution) or median (upper and lower quartiles) (skewed distribution).

Figure 2: Box graph of characteristic parameters with statistically significant difference in Luminal A and Luminal B patients.
Diagnostic power of kurtosis, heterogeneity and entropy for ER-positive breast cancer subtypes

The diagnostic power of kurtosis, heterogeneity and entropy for ER-positive breast cancer subtypes were shown in Figure 3. The AUC of kurtosis, heterogeneity and entropy were 0.832, 0.859 and 0.891, respectively, and the differential diagnosis of entropy was the highest. The sensitivity of entropy ≤4.22 for Luminal B type was 90.62% and the specificity was 78.95%.

Discussion

At present, the clinical treatment plan for breast cancer is mainly based on molecular typing. For most patients, Luminal A requires only endocrine therapy and has a good prognosis, while Luminal B is usually treated with chemotherapy and endocrine therapy (13,14). Compared with clinical commonly used immunohistochemistry to determine molecular typing, texture analysis does not depend on the subjective factors and clinical experience of physicians, and assists in the diagnosis of diseases by quantitatively analyzing the texture characteristic parameters of images (15). This study preliminarily demonstrated the feasibility of DCE-MRI texture analysis to distinguish Luminal A and Luminal B breast cancer. Features extracted from DCE-MRI can be initially identified as potential biomarkers for identifying Lumina A and B of breast cancer at molecular subtypes.

In clinical work, doctors’ diagnosis of the disease depends to a large extent on the morphology of the lesion. Due to the limitations of the texture analysis software used in this study, only one morphological index of the lesion size was extracted. We believed that this may be related to the time of patient visit and the time of pathological diagnosis, which needed to be further verified by dynamic analysis under the same conditions.

In this study, kurtosis in Luminal A subtype breast cancer was lower than Luminal B subtype, while heterogeneity and entropy in the former has higher than the latter. Kurtosis is a parameter that describes the steepness of the data distribution curve, and is considered to be a biomarker of tumor heterogeneity (16), which is inversely related to treatment effectiveness (17). This was consistent with the clinical features of the Luminal A subtype, which had a lower invasiveness, a better prognosis, and a higher survival rate (18). Patients with grade 3 breast cancer or tumors with high expression of Ki-67 were associated with higher kurtosis and lower diffusivity coefficients (19). Diffusion Kurtosis at 3.0 T can be used as an in vivo imaging marker for breast cancer characterization (20).

Skewness is a parameter that describes the symmetry of the distribution of data curves (21). The skew of the normal distribution is zero, and the skewness of any symmetric data should be close to zero (22). A negative value of the skewness indicates data tilted to the left, and a positive value of the skewness indicates data tilted to the right. The two Luminal subtypes are all skewed to the left, and the Luminal B subtype is more oblique to the left, but the two subtypes have no statistical difference. This may be related to the invasive ductal carcinoma of the breast, the limitation of pathological types, and the small number of cases, so further research is needed. Inhomogeneity and entropy reflect the randomness and average information of the histogram. In the Luminal B subtype histogram, the pixel gray-scale frequency distribution is concentrated and the signal intensity is relatively uniform, while the Luminal A sub-pixel gray-scale frequency distribution is significantly reduced and uneven. This may be due to the fact that the Luminal B subtype has a stronger biological proliferative capacity and can take in more similar voxels, so the voxels seem to be more uniform.

By analyzing the ROC curves of three texture indicators (entropy, inhomogeneity and kurtosis) which were statistically different for identifying Luminal subtype breast cancer, it was concluded that the diagnostic efficiency of all three were high. The diagnostic efficiency of entropy
was the highest. AUC reached 0.891, and the sensitivity of Luminal B breast cancer was higher when the entropy was less than 4.22, and the specificity was slightly lower. Holli-Helenius et al. (23) identified the Luminal subtype breast cancer by enhancing the pre-T1 weighted image (T1WI) plain image texture analysis, and the entropy diagnostic efficiency was also higher, with an AUC of 0.828. The mammography was used to analyze the benign and malignant breast nodules, the entropy had the highest discriminative efficiency, and the sensitivity and specificity were 89.0% and 72.0%, respectively (24). It indicated that entropy can be used as a best single texture indicator to identify benign and malignant small nodules. It could be seen that entropy was a commonly used parameter in texture analysis and had high diagnostic efficiency.

There are some limitations in this study: (I) because non-tumor breast cancer lesions were scattered and diffuse, the boundary determination was difficult for physicians to perform manual segmentation, and the non-tumor type breast cancer was not included to reduce the difference between observers due to difficulty in boundary recognition; (II) sample size was not enough, and was a single-center study; (III) independent analysis of several parameters commonly used in texture analysis, no systematic omics study; (IV) this study was only for ER-positive breast cancer subtype prediction, the lymph node metastasis had not been included in the research scope.

In summary, DCR-MRI texture analysis can accurately predict ER-positive breast cancer typing before surgery, and entropy was most likely to become a potential imaging marker, providing clinicians with corresponding reference value. But further study is still needed to verify our results.

**Acknowledgments**

_Funding_: None.

**Footnote**

_Conflicts of Interest_: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

**Ethical Statement**: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Before performing this study, all patients signed informed consent form, and this study was approved by the Ethics Committee of The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology.

_Open Access Statement_: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**
